File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Case report: dysgeusia, strawberry tongue, and psoriatic eruptions after combination treatment with adalimumab, sulfasalazine, and etoricoxib for ankylosing spondylitis

TitleCase report: dysgeusia, strawberry tongue, and psoriatic eruptions after combination treatment with adalimumab, sulfasalazine, and etoricoxib for ankylosing spondylitis
Authors
Keywordsadalimumab
adverse drug reaction
case report
dysgeusia
psoriasis-like eruption
strawberry tongue
Issue Date3-Feb-2025
PublisherFrontiers Media S.A.
Citation
Frontiers in Medicine, 2025, v. 12 How to Cite?
AbstractBackground: Tumor necrosis factor blockers can suppress immune system and lead to various adverse drug reactions, including deaths. We present a rare case of dysgeusia, strawberry tongue, and psoriasis-like eruptions after simultaneous administration of adalimumab, sulfasalazine, and etoricoxib. Case description: A 36 year-old male with ankylosing spondylitis presented with progressive loss of taste for 3 months and rashes on his upper trunk for 5 days. He had been receiving adalimumab, sulfasalazine, and etoricoxib for 9 months. After self-discontinuing the medicines, the rashes gradually subsided. On examination, swollen and red strawberry tongue were noticed. Acinetobacter pittii was isolated by sputum culture. The patient refused any treatment. During follow-up, recurrent dispersed papules/macules and desquamation appeared on his upper trunk, with erythema and erosion in umbilical region. Subsequently, generalized scalp erythema, exudates, scabs, hair bundles, redness and desquamation behind ears occurred. The tongue, taste, and skin lesions resolved sequentially and steadily until complete recovery. Outcome: He remained in remission during 4 years follow-up. The total course of disease was around 10 months. Discussion: Clinicians should be cautious of the adverse drug reactions/events due to adalimumab, sulfasalazine, and etoricoxib. Rational use of medicines is advocated.
Persistent Identifierhttp://hdl.handle.net/10722/365906

 

DC FieldValueLanguage
dc.contributor.authorCui, Binglin-
dc.contributor.authorLin, Jing-
dc.contributor.authorHuang, Yuanchun-
dc.contributor.authorZhu, Huachen-
dc.contributor.authorZou, Jinbo-
dc.contributor.authorQin, Jiesheng-
dc.contributor.authorPan, Hui-
dc.contributor.authorChen, Jian-
dc.date.accessioned2025-11-12T00:36:27Z-
dc.date.available2025-11-12T00:36:27Z-
dc.date.issued2025-02-03-
dc.identifier.citationFrontiers in Medicine, 2025, v. 12-
dc.identifier.urihttp://hdl.handle.net/10722/365906-
dc.description.abstractBackground: Tumor necrosis factor blockers can suppress immune system and lead to various adverse drug reactions, including deaths. We present a rare case of dysgeusia, strawberry tongue, and psoriasis-like eruptions after simultaneous administration of adalimumab, sulfasalazine, and etoricoxib. Case description: A 36 year-old male with ankylosing spondylitis presented with progressive loss of taste for 3 months and rashes on his upper trunk for 5 days. He had been receiving adalimumab, sulfasalazine, and etoricoxib for 9 months. After self-discontinuing the medicines, the rashes gradually subsided. On examination, swollen and red strawberry tongue were noticed. Acinetobacter pittii was isolated by sputum culture. The patient refused any treatment. During follow-up, recurrent dispersed papules/macules and desquamation appeared on his upper trunk, with erythema and erosion in umbilical region. Subsequently, generalized scalp erythema, exudates, scabs, hair bundles, redness and desquamation behind ears occurred. The tongue, taste, and skin lesions resolved sequentially and steadily until complete recovery. Outcome: He remained in remission during 4 years follow-up. The total course of disease was around 10 months. Discussion: Clinicians should be cautious of the adverse drug reactions/events due to adalimumab, sulfasalazine, and etoricoxib. Rational use of medicines is advocated.-
dc.languageeng-
dc.publisherFrontiers Media S.A.-
dc.relation.ispartofFrontiers in Medicine-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectadalimumab-
dc.subjectadverse drug reaction-
dc.subjectcase report-
dc.subjectdysgeusia-
dc.subjectpsoriasis-like eruption-
dc.subjectstrawberry tongue-
dc.titleCase report: dysgeusia, strawberry tongue, and psoriatic eruptions after combination treatment with adalimumab, sulfasalazine, and etoricoxib for ankylosing spondylitis-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3389/fmed.2025.1419922-
dc.identifier.scopuseid_2-s2.0-85218223976-
dc.identifier.volume12-
dc.identifier.eissn2296-858X-
dc.identifier.issnl2296-858X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats